<DOC>
	<DOCNO>NCT02973672</DOCNO>
	<brief_summary>This study evaluate safety performance SGM-101 , Carcinoembryonic Antigen ( CEA ) -specific chimeric antibody conjugate NIR emit fluorochrome , visualization CEA-expressing cancer surgery . SGM-101 inject 2 4 day surgery visualize use optimize camera system .</brief_summary>
	<brief_title>Phase I SGM-101 Patients With Cancer Colon , Rectum Pancreas</brief_title>
	<detailed_description>Surgery important therapy patient cancer colon , rectum pancreas . Complete resection , crucial factor prognosis patient , challenge surgeon rely visual appearance palpation discriminate tumor normal tissue . Carcinoembryonic antigen ( CEA ) tumor-specific marker highly express number tumor epithelial origin ( colorectal carcinoma pancreas carcinoma ) minimally express normal adult tissue . The compound study research project SGM-101 , CEA-specific chimeric antibody conjugate near-infrared ( NIR ) emit moiety . The hypothesis , follow preoperative iv administration SGM-101 patient carcinoma colon , rectum pancreas , SGM-101 bind CEA express cancer cell cell visualize NIR fluorescence image system , thereby increase chance radical resection .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Patients age 18 year old ; Patient schedule eligible surgery clinical diagnosis cancer colon , rectum cancer pancreas ; Both pancreatic colorectal cancer patient : Circulating plasma CEA ≥ upper limit normal range ( eg ≥ 3.0 ng / ml ) ; Patient suffer recurrence metastasis colorectal cancer : Rising circulate plasma CEA Patients capable willing give inform consent study specific procedure . Anticancer therapy ( e.g . chemotherapy , radiotherapy ( except routine preoperative radiotherapy colorectal cancer ) , target therapy , concomitant systemic immune therapy , experimental therapy ) within 4 week inclusion ; History clinically significant allergy ; Circulating plasma concentration CEA ≥ 300 ng / ml ; Other malignancy either currently active diagnose last 5 year , except adequately treat situ carcinoma cervix basal squamous cell skin carcinoma ; Patients pregnant breastfeeding ( pregnancy rule assay βhCG plasma within 4±1 week prior administration conjugate ) , lack effective contraception male female patient reproductive potential ; Laboratory abnormality define : Colorectal cancer patient : Aspartate AminoTransferase , Alanine AminoTransferase , Gamma Glutamyl Transferase ) Alkaline Phosphatase level 5 time ; Total bilirubin 2 time Upper Limit Normal ( ULN ) ; Both pancreatic colorectal cancer patient : Serum creatinine 1.5 time ULN ; Absolute neutrophils count 1.5 x 109/L ; Platelet count 100 x 109/L ; Hemoglobin 4 mmol/L ( female ) 5 mmol/l ( male ) ; Known positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAG ) hepatitis C virus ( HCV ) antibody patient untreated serious infection ; Any condition investigator considers potentially jeopardize patient ' wellbeing study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fluorescence</keyword>
	<keyword>Surgery</keyword>
	<keyword>Cancer</keyword>
	<keyword>SGM-101</keyword>
	<keyword>Near Infrared</keyword>
	<keyword>Immunophotodetection</keyword>
</DOC>